scholarly journals Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis

2012 ◽  
Vol 90 (9) ◽  
pp. 693-698 ◽  
Author(s):  
Kristian Ängeby ◽  
Pontus Juréen ◽  
Gunnar Kahlmeter ◽  
Sven Hoffner ◽  
Thomas Schön
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Antimicrobial Susceptibility Testing

scholarly journals On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex

2021 ◽  
Vol 59 (4) ◽  
Author(s):  
Claudio U. Köser ◽  
Sophia B. Georghiou ◽  
Thomas Schön ◽  
Max Salfinger
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Antimicrobial Susceptibility Testing ◽  
World Health ◽  
The European Union ◽  
Reference Standard ◽  
Resistance Mutations ◽  
Content Type ◽  
Indicator Tube

ABSTRACT In a recent report of a systematic review of critical concentrations (CCs), the World Health Organization (WHO) lowered the rifampin (RIF) CC for antimicrobial susceptibility testing (AST) of the Mycobacterium tuberculosis complex using Middlebrook 7H10 medium and the Bactec Mycobacterial Growth Indicator Tube (MGIT) 960 system from 1 to 0.5 μg/ml. The previous RIF CC for 7H10 had been in use for over half a century. Because it had served as the de facto reference standard, it contributed to the endorsement of inappropriately high CCs for other AST methods, including the U.S. Food and Drug Administration (FDA)-approved MGIT system. Moreover, this resulted in confusion about the interpretation of seven borderline resistance mutations in rpoB (i.e., L430P, D435Y, H445L, H445N, H445S, L452P, and I491F). In this issue of the Journal of Clinical Microbiology, Shea et al. (J Clin Microbiol 59:e01885-20, 2021, https://doi.org/10.1128/JCM.01885-20) provide evidence that the CC endorsed by the Clinical and Laboratory Standards Institute for the Sensititre MYCOTB system, which is not FDA approved but is CE-IVD marked in the European Union, is likely also too high. These findings underscore the importance of calibrating AST methods against a rigorously defined reference standard, as recently proposed by the European Committee on Antimicrobial Susceptibility Testing, as well as the value of routine next-generation sequencing for investigating discordant AST results.

scholarly journals Verification of Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis

2006 ◽  
Vol 44 (5) ◽  
pp. 1921-1921
Author(s):  
L. Hall ◽  
K. A. Doerr ◽  
W. S. Harmsen ◽  
N. L. Wengenack ◽  
G. D. Roberts
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Antimicrobial Susceptibility Testing

scholarly journals Reliability of the MB/BacT System for Testing Susceptibility of Mycobacterium tuberculosis Complex Isolates to Antituberculous Drugs

2000 ◽  
Vol 38 (2) ◽  
pp. 872-873 ◽  
Author(s):  
Francesca Brunello ◽  
Roberta Fontana
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Mycobacterium Tuberculosis Complex ◽  
Antimicrobial Susceptibility Testing ◽  
Clinical Isolates ◽  
Tuberculosis Complex ◽  
Antituberculous Drugs ◽  
Testing Susceptibility

The susceptibility of 115 Mycobacterium tuberculosiscomplex clinical isolates to isoniazid, streptomycin, ethambutol, and rifampin was assessed by the MB/BacT and BACTEC 460TB systems. The correlation between the two tests was 98.3% for isoniazid, 100% for streptomycin and rifampin, and 95.8% for ethambutol. Turnaround times for antimicrobial susceptibility testing ranged from 5 to 11 days (median, 8.5 days) for MB/BacT and from 4 to 8 days (median, 6 days) for BACTEC 460TB.

Sign in / Sign up

Export Citation Format

Share Document